Thrombopoietin, Recombinant, Human (TPO, Mpl-ligand, MGDF)

Thrombopoietin (Tpo), the ligand for the receptor encoded by the c-Mpl proto-oncogene, is a key regulator of megakaryocytopoiesis and thrombopoiesis in vitro and in vivo. The cDNAs for Tpo have recently been cloned from canine, murine and human sources. The proteins from these three species are highly conserved, exhibiting from 69-75% sequence identity at the amino acid level. Human Tpo cDNA encodes a 353 amino acid residue protein with a 21 amino acid residue signal peptide that is cleaved to yield the 332 amino acid residue mature protein. Two distinct domains, separated by a pair of arginine residues that may be a proteolytic cleavage site, have been identified in Tpo: the amino terminal region exhibiting sequence homology to erythropoietin and the carboxy terminal region containing multiple potential N-linked glycosylation sites. Recombinant Tpo has now been shown to stimulate the maturation, as well as the proliferation, of megakaryocytes and may have important therapeutic applications for the treatment of various clinical conditions associated with thrombocytopenia. Recombinant Human TPO is approximately 80kD, consisting of a 332 amino acid residue with a predicted molecular mass of approximately 35kD. As a result of glycosylation, the recombinant protein migrates with an apparent molecular mass of 80

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

T5050-10B

Size

2ug

Form

Supplied as a lyophilized powder in 20mM sodium citrate buffer, pH 6.9. Reconstitute with sterile ddH2O, 0.1% HSA or BSA to (same/more than)100ug/ml, which can then be further diluted to other aqueous solutions.

Purity

~ 97% as determined by Analysis by RP-HPLC, Anion-exchange FPLC or Analysis by reducing and non-reducing SDS-PAGE Silver Stained.

References

1. Nucleic Acids Res 2006 May 5;34(8):2355-63 2. Circulation 2006 May 9;113(18):2211-20 3. Haematologica 2006 Apr;91(4):445-51 4. Curr HIV Res 2006 Jan;4(1):107-16 5. Exp Hematol 2006 Jan;34(1):87-96 6. Exp Hematol 2006 Jan;34(1):82-6